Table 3 Characteristics of patients showing recurrence
Case | T stage | iPSA | Gleason score | Risk category | Hormonal therapy (months) | PSA failure (months) | Clinical failure (months) | Site of recurrence | Status at last follow-up |
|---|---|---|---|---|---|---|---|---|---|
1 | 2a | 35.29 | 4 + 5 | H | 45 | 31 | 30 | Bone | Alive |
2 | 3b | 82.98 | 5 + 4 | H | 32 | 13 | 14 | Bone | Alive |
3 | 1c | 14.78 | 3 + 4 | I | NA | 38 | 42 | Hormone treatment | Alive |
4 | 1c | 11.4 | 3 + 4 | I | NA | 20 | 24 | Lymph node, lung | Alive |
5 | 1c | 10.9 | 4 + 4 | H | NA | 24 | NA | NA | Alive |
6 | 1c | 13.291 | 3 + 4 | I | NA | 27 | NA | NA | Alive |
7 | 2c | 7.5 | 3 + 3 | I | 10 | NA | 12 | Bone | Alive |